Sign in

You're signed outSign in or to get full access.

PP

Praxis Precision Medicines, Inc. (PRAX)·Q3 2025 Earnings Summary

Executive Summary

  • Reported Q3 2025 net loss of $73.9M and diluted EPS of $-3.36; EPS modestly beat Wall Street consensus of $-3.47*, while revenue was $0 versus consensus of ~$59.44k* .
  • Announced first-ever successful Phase 3 program in essential tremor: both Essential3 studies for ulixacaltamide met primary endpoints; pre-NDA meeting with FDA scheduled for Q4 2025, positioning for first NDA submission .
  • Relutrigine program aligned with FDA: planned Q4 2025 interim analysis of EMBOLD that, if positive, may serve as the basis for an NDA in early 2026; EMERALD (broad DEEs) enrollment underway .
  • Pro forma cash and investments of ~$956M (including ~$567M net proceeds from Oct 2025 offering) extend runway into 2028, supporting multiple late-stage readouts and potential launch preparation .

What Went Well and What Went Wrong

What Went Well

  • Essential tremor success: “first ever successful Phase 3 program… with both studies… meeting their primary endpoints” and strong mADL11 improvements; management is advancing to a pre-NDA discussion in Q4 2025 .
  • Vormatrigine execution: POWER1 recruitment completed with topline in 1H 2026; POWER2 initiated, targeting full enrollment in 2H 2026; RADIANT data demonstrated robust efficacy and tolerability signals supporting registrational path .
  • Regulatory alignment on relutrigine: FDA agreed the planned EMBOLD interim analysis, if positive, may support an early 2026 NDA; EMERALD registrational study began in Q3 2025 .

What Went Wrong

  • Operating intensity: R&D expense rose to $65.8M (+$23.9M YoY), widening quarterly net loss to $73.9M vs $51.9M YoY, reflecting acceleration across Cerebrum and Solidus platforms .
  • No revenue: Collaboration revenue was $0 in Q3 2025 versus $0.3M in Q3 2024, following UCB’s option exercise eliminating further service obligations under that agreement .
  • Prior quarter trial management learnings: In Q2 RADIANT, discontinuations were ~23% in open-label setting; management plans clearer investigator guidance on background ASM dose reduction in POWER trials to improve tolerability and continuity .

Financial Results

P&L and EPS (USD)

MetricQ1 2025Q2 2025Q3 2025
Collaboration Revenue ($)$0 $0 $0
Research & Development ($MM)$60.806 $63.006 $65.797
General & Administrative ($MM)$13.922 $13.061 $12.562
Total Operating Expenses ($MM)$74.728 $76.067 $78.359
Other Income, net ($MM)$5.432 $4.940 $4.425
Net Loss ($MM)$(69.296) $(71.127) $(73.934)
Diluted EPS ($)$(3.29) $(3.31) $(3.36)
Weighted Avg. Shares (mm)21.056 21.475 21.977

Notes: All figures unaudited; MM denotes millions.

Balance Sheet KPIs (USD)

MetricQ1 2025Q2 2025Q3 2025
Cash & Cash Equivalents ($MM)$165.567 $157.415 $149.527
Marketable Securities ($MM)$306.456 $289.229 $239.638
Cash + Investments ($MM)$472.023 $446.644 $389.165
Accounts Payable ($MM)$22.909 $28.832 $30.819
Accrued Expenses ($MM)$15.547 $19.021 $21.628
Additional Paid-in Capital ($MM)$1,344.577 $1,380.978 $1,394.088

Pro forma: ~$956M cash and investments post-Oct 2025 offering; ~$567M net proceeds received in Oct 2025 .

Estimates vs Actuals (Q3 2025)

MetricConsensusActual
Primary EPS (USD)-3.47*-3.36
Revenue (USD)59,440*0
EPS Estimates Count14*—
Revenue Estimates Count14*—

Values with asterisk retrieved from S&P Global.

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
Ulixacaltamide Essential3 toplineQ3 2025“Early fall 2025” topline expected Positive Phase 3 results; pre-NDA mtg in Q4 2025 Raised (success)
Ulixacaltamide NDA pathQ4 2025 / 2026Determine NDA sufficiency after both studies Pre-NDA meeting scheduled Q4 2025 Clarified timeline
Vormatrigine POWER11H 2026On track to complete in Q4 2025 Recruitment completed; topline expected 1H 2026 Timing updated
Vormatrigine POWER22H 2026Initiate Q3 2025; complete 2H 2026 Started; expected fully enrolled 2H 2026 Maintained
Vormatrigine POWER31H 2026Initiate 1H 2026 Expected to initiate 1H 2026 Maintained
Relutrigine EMBOLD (Cohort 2)1H 2026Topline no later than 1H 2026 Interim analysis in Q4 2025 may support NDA in early 2026 Accelerated regulatory path
Relutrigine EMERALD (broad DEEs)2026Initiated; complete enrollment in 2026 Enrollment began in Q3 2025; expected complete 2H 2026 Maintained
Elsunersen EMBRAVE (Part A)1H 2026Topline 1H 2026 On track for topline 1H 2026 Maintained
Elsunersen EMBRAVE32026Initiated; recruit through 2026 Recruiting; expected complete in 2026 Maintained
Cash RunwayThrough 2028“Runway into 2028” Into 2028; pro forma ~$956M cash & investments Strengthened

Earnings Call Themes & Trends

Note: A Q3 2025 earnings call transcript was not available in the document set; trends incorporate Q2 2025 call and Q3 press release.

TopicPrevious Mentions (Q1 & Q2)Current Period (Q3 2025)Trend
Essential tremor programQ1: Interim futility in Essential3 Study 1; proceed to complete both studies First-ever successful Phase 3 program; pre-NDA scheduled Q4 2025 Strongly positive
Vormatrigine efficacy/tolerabilityQ2 call: “best-in-disease” efficacy; plan POWER2 doses incl. 40mg; manage background ASM to reduce AEs POWER1 recruitment completed; POWER2 started; AE management learnings embedded Execution strengthening
Regulatory alignment (relutrigine)Q2: BTD received; EMERALD initiated; strong EMBOLD progress FDA alignment for interim analysis as basis for NDA; EMERALD enrolling Acceleration
Cash runway & fundingQ1/Q2: runway into 2028 ~$567M offering; pro forma ~$956M; runway into 2028 Strengthened
Patient recruitment engineQ2: 99 screened; 61 dosed in RADIANT by July 25; robust site engine POWER1 completed recruitment; ENERGY program ~20k patients Scaling
Mood endpointsQ2: anecdotal improvements; adding mood/depression endpoint in POWER2 Incorporated in POWER2 per Q2 plans Formalizing assessment

Management Commentary

  • “It’s been a monumental few months… culminating in the first ever successful Phase 3 program of an investigational drug in ET… We have been granted a pre-NDA meeting with the FDA and look forward to discussing Praxis’ first NDA submission.” — Marcio Souza, President & CEO .
  • “We completed comprehensive discussions with the FDA… proposed interim analysis, if positive, may serve as the basis of the NDA submission in early 2026.” — Company statement on relutrigine .
  • On vormatrigine: “Best-in-disease efficacy… rapid seizure reduction, favorable safety, ease of use… RADIANT results bolster confidence in ongoing and upcoming studies.” — Q2 call prepared remarks .

Q&A Highlights

Note: Q3 2025 call transcript unavailable; highlights are from Q2 2025 call.

  • Background therapies: Strong efficacy across sodium channel blockers, SV2A modulators, and cenobamate; >55% response even atop aggressive cenobamate regimens; plan clearer guidance on background ASM dose reduction to mitigate AEs .
  • Exposure-response and dosing: Rapid steady-state reached by week 1–2; efficacy deepened over time; POWER2 to test 20/30/40mg; mood endpoints added based on site feedback .
  • Placebo and discontinuations: Expect lower placebo rates in POWER1 due to refractory population and site quality; discontinuations in open-label setting often tied to background ASM management; resolved with dose adjustments .
  • Potential disease modification: Hypothesis of resetting neuronal activity set-point with precision sodium-channel modulation; mood improvements seen anecdotally, to be formally assessed .

Estimates Context

  • EPS modest beat: Q3 2025 EPS of $-3.36 vs consensus $-3.47*; magnitude small, but favorable relative to expectations .
  • Revenue: Reported $0 vs consensus ~$59.44k*, reflecting continued focus on R&D rather than revenue generation .
  • Target price consensus (point-in-time reference): $323.93*; number of estimates: EPS (14*), Revenue (14*), Target Price (15*).
    Values with asterisk retrieved from S&P Global.

Guidance Changes

(See table above for full details.)

  • Key near-term catalysts: Ulixacaltamide pre-NDA meeting (Q4 2025); Relutrigine EMBOLD interim analysis (Q4 2025) potentially enabling early 2026 NDA; POWER1 topline (1H 2026); EMERALD and EMBRAVE program milestones through 2026 .

Key Takeaways for Investors

  • Ulixacaltamide’s unprecedented Phase 3 ET success creates a near-term regulatory catalyst (pre-NDA Q4 2025) and potential first commercial launch path in a large, underserved indication .
  • Relutrigine’s FDA-aligned interim analysis (Q4 2025) may accelerate time-to-NDA for SCN2A/SCN8A DEEs, broadening the late-stage optionality alongside EMERALD .
  • Vormatrigine’s RADIANT data and completed POWER1 recruitment de-risk efficacy/tolerability; POWER2 underway with dose optimization and mood endpoints, supporting best-in-disease positioning .
  • Strengthened capital position (pro forma ~$956M) and runway into 2028 supports multiple registrational programs and potential launch preparation without near-term financing overhang .
  • Near-term trading catalysts center on regulatory interactions (ulixacaltamide pre-NDA; relutrigine interim) and any additional clinical disclosures; stock sensitivity likely tied to perceived probability/pace of NDA filings .
  • Medium-term thesis: Platform credibility across precision CNS (Cerebrum and Solidus) with multiple shots-on-goal (ET, common epilepsy, DEEs) and recruitment engine advantages may support durable value creation as readouts stack through 2026 .
  • Risk watch: Elevated R&D spend and lack of revenue are expected in development stage; execution risk around trial timelines and regulatory outcomes remains the primary determinant of value .

Source Documents Read

  • Q3 2025 Form 8-K, Item 2.02, and press release (Exhibit 99.1) .
  • Q2 2025 Form 8-K and press release; RADIANT presentation .
  • Q1 2025 Form 8-K and press release .
  • Q2 2025 earnings call transcript .
  • Additional PR: investor events and earnings webinar replay availability (Nov 5, 2025) .